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Abstract
Van der Vorst and coworkers recently illustrated the large variability
in furosemide regimens used in their unit. This finding at least
suggests that we need more data on the pharmacokinetics and
pharmacodynamics of this drug in neonates during treatment with
extracorporeal membrane oxygenation, in order to ensure quality of
care and safety, and to promote evidence-based prescription. The
implementation of population pharmacokinetic models can further
increase both the feasibility of such studies and the relevance of
the results generated.
Although the general principles of clinical pharmacology
apply to neonates and young infants, the characteristics of
this population warrant a specific approach. The relative body
water content, fat distribution and muscle mass are markedly
different in foetal than in neonatal and paediatric groups.
Almost all phase 1 and phase 2 hepatic clearance processes
have a distinct isoenzyme-specific ontogeny, whereas renal
clearance in early neonatal life is limited and depends almost
entirely on glomerular filtration rate; the result of these factors
is that the body’s clearance of pharmacological agents
evolves in a drug-specific, age-dependent manner.
Extracorporeal membrane oxygenation (ECMO) further
affects the pharmacokinetics and pharmacodynamics
(PK/PD) of drugs. It is therefore mandatory that population-
specific data in neonates on drug-specific PK/PD during
ECMO be collected in order to ensure quality of care and
safety, and to promote evidence-based prescription.
Recently in Critical Care, Van der Vorst and coworkers [1]
described the Rotterdam group’s experience on the
administration of intravenous furosemide to neonates under-
going ECMO. The authors report considerable variability in
furosemide regimens used without any benefit from additional
bolus administration in their cohort, using urine output during
the first 24 hours after initiation and time to reach 6 ml/kg per
hour as pharmacodynamic outcome variables.
The appropriateness of initiating ECMO in neonates with
respiratory insufficiency has been firmly established by the
UK-ECMO trial [2], but data on the PK/PD of drugs that are
frequently prescribed in these neonates are less robust. Van
der Vorst and coworkers [1] correctly identified that the
retrospective design of their study prevented them from
drawing definitive conclusions, but they highlighted a need
for a prospective PK/PD study to evaluate a predefined
continuous furosemide regimen. Population pharmacokinetics
provides clinical researchers with a potent tool with which to
improve both the relevance and the feasibility of studies on
developmental pharmacology in neonates.
Population modelling using mixed effects models provides a
means to study variability in drug responses among
individuals who are representative of those in whom the drug
will be used clinically. These models have advantages for
paediatric studies for the following reasons: they can be used
to analyze sparse data; sampling times are not crucial; they
can be fitted around clinical procedures; and, finally,
individuals with missing data may still be included. Covariates
account for the predictable component of the variability
between individuals. Growth and development are two major
aspects in children that are not seen in adults. These aspects
can be investigated using size and age as covariates [3,4].
Mulla and coworkers [5,6] recently reported on the
pharmacokinetics of midazolam and vancomycin using
population modelling. They identified important changes in
both clearance and volume of distribution of these drugs
during ECMO treatment, in addition to the normal changes in
these factors that would be expected to occur with age and
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maturity. Similar trends were documented by Peters and
coworkers [7] in their evaluation of morphine pharmaco-
kinetics during venoarterial ECMO in neonates. In general,
there is an increase in distribution volume, which is most
prominent in water soluble drugs, and a decrease in drug
clearance.
Whether to initiate any treatment is a decision balanced by a
cost-benefit consideration based on potential effects and
side effects. The use of furosemide has been associated with
nonconductive hearing loss at age 5 to 8 years; continuous
administration of furosemide necessitates additional intra-
venous access; and there remains uncertainty regarding
pharmacodynamic end-points [1,8]. We therefore strongly
agree with Van der Vorst and coworkers [1] that there is a
need for a prospective PK/PD study on the use of furosemide
in neonates during ECMO. The hearing loss associated with
furosemide use suggests that long-term follow up is needed
in neonates who have undergone ECMO treatment, and the
implementation of population pharmacokinetic models can
further increase both the feasibility of such studies and the
relevance of the results obtained, as illustrated by the work of
Mulla [5,6] and Peters [7] and their groups.
Following documentation of the advantages of using ECMO
to manage neonatal respiratory insufficiency in terms of both
mortality and morbidity, the evaluation of pharmacotherapy
during neonatal ECMO should become a second step toward
a more evidence-based approach to these patients.
Competing interests
The authors declare that they have no competing interests.
References
1. Van der Vorst MM, Wildschut E, Houmes RJ, Gischler SJ, Kist-van
Holthe JE, Van der Heijden AJ, Burggraaf J, Tibboel D: Evaluation
of furosemide regimens in neonates treated with extracorpo-
real membrane oxygenation. Crit Care 2006, 10:R168.
2. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H:
Cost-effectiveness of neonatal extracorporeal membrane oxy-
genation based on 7-year results for the United Kingdom Col-
laborative ECMO trial. Pediatrics 2006, 117:1640-1649.
3. Anderson BJ, Allegaert K, Holford N: Population clinical phar-
macology of children: general principles. Eur J Pediatr 2006,
165:741-746.
4. Anderson BJ, Allegaert K, Holford N: Population clinical phar-
macology of children: modelling covariate effects. Eur J
Pediatr 2006, 165:819-829.
5. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR: Phar-
macokinetics of midazolam in neonates undergoing extracor-
poreal membrane oxygenation. Anesthesiology 2003,  99:
275-282.
6. Mulla H, Pooboni S: Population pharmacokinetics of van-
comycin in patients receiving extracorporeal membrane oxy-
genation. Br J Clin Pharmacol 2005, 60:265-275.
7. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D: Mor-
phine metabolite pharmacokinetics during venoarterial extra
corporeal membrane oxygenation in neonates. Clin Pharma-
cokinet 2006, 45:705-714.
8. Robertson CM, Tyebkhan JM, Peliowski A, Etches PC, Cheung
PY: Ototoxic drugs and sensorineural hearing loss following
severe neonatal respiratory failure. Acta Paediatr 2006,  95:
214-223.